Asset profile
Lintuzumab-Ac225
Radiopharmaceutical
Evidence outlook · registrational
Acute Myeloid Leukemia: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT02575963: The study enrolled 40 participants without randomization, blinding, or a comparator arm, so outcomes cannot be directly attributed to Lintuzumab-Ac225 relative to another treatment. Its primary remission result is not available because no results have been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.